Astria Therapeutics Inc. (ATXS), which shared positive initial proof-of-concept results from its ALPHA-STAR trial in March, has a couple of noteworthy developments on the horizon.
ALPHA-STAR is a phase Ib/II proof-of-concept trial assessing single and multiple doses of the company's drug candidate STAR-0215 in patients with Hereditary Angioedema (HAE) types I and II.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.